PMID- 23517391
OWN - NLM
STAT- MEDLINE
DCOM- 20130726
LR  - 20161021
IS  - 0125-877X (Print)
IS  - 0125-877X (Linking)
VI  - 31
IP  - 1
DP  - 2013 Mar
TI  - Comparison of the efficacy and safety of mometasone furoate to other inhaled 
      steroids for asthma: a meta-analysis.
PG  - 26-35
AB  - BACKGROUND: It has been of great interest whether mometasone furoate (MF) is 
      better than other inhaled corticosteroids (ICSs) as the controller therapy in 
      patients with moderate or severe asthma who had previously been taking ICSs. 
      OBJECTIVE: The aim of this meta-analysis is to thoroughly compare the efficacy 
      and safety of MF versus other ICSs with equipotent daily doses in those patients. 
      METHODS: Relative databases were searched. Randomised controlled trials of more 
      than or equal to 4 weeks' treatment duration comparing MF with other ICSs were 
      reviewed. RESULTS: Six trials with 1354 randomised patients met the inclusion 
      criteria. Significant differences favouring MF were found in all indices of 
      pulmonary function. MF was superior compared to other ICSs in decreasing the 
      frequency of rescue medication use and morning difficulty breathing score. There 
      was no significant difference between MF and other ICSs therapy in morning 
      wheezing score, cough score and percentage of patients with no nocturnal 
      awakenings due to asthma. For the treatment-related adverse effects (AEs), 
      treatment-related severe AEs, discontinuations due to AEs and some common symptom 
      of AEs, MF was all similar to other ICSs in their incidence. CONCLUSIONS: In 
      adult patients with moderate or severe asthma who had previously been taking 
      ICSs, MF was superior to other ICSs with equipotent daily doses as controller 
      monotherapy in improving pulmonary function and decreasing the frequency of 
      rescue medication use, and was similar to other ICSs in the incidence of AEs. 
      These results demonstrated the priority of MF in asthma therapy.
FAU - Yang, Danlei
AU  - Yang D
AD  - Department of Respiratory and Critical Care Medicine, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Wang, Jianmiao
AU  - Wang J
FAU - Bunjhoo, Hansvin
AU  - Bunjhoo H
FAU - Xiong, Weining
AU  - Xiong W
FAU - Xu, Yongjian
AU  - Xu Y
FAU - Zhao, Jianping
AU  - Zhao J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Thailand
TA  - Asian Pac J Allergy Immunol
JT  - Asian Pacific journal of allergy and immunology
JID - 8402034
RN  - 0 (Pregnadienediols)
RN  - 0 (Steroids)
RN  - 04201GDN4R (Mometasone Furoate)
SB  - IM
MH  - Administration, Inhalation
MH  - Asthma/*drug therapy
MH  - Humans
MH  - Mometasone Furoate
MH  - Odds Ratio
MH  - Pregnadienediols/administration & dosage/adverse effects/*therapeutic use
MH  - Respiratory Function Tests
MH  - Steroids/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2013/03/23 06:00
MHDA- 2013/07/28 06:00
CRDT- 2013/03/23 06:00
PHST- 2012/05/24 00:00 [received]
PHST- 2012/08/17 00:00 [accepted]
PHST- 2013/03/23 06:00 [entrez]
PHST- 2013/03/23 06:00 [pubmed]
PHST- 2013/07/28 06:00 [medline]
PST - ppublish
SO  - Asian Pac J Allergy Immunol. 2013 Mar;31(1):26-35.